Yahoo · Nov 6, 2026
IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock Up
Ironwood's Q3 earnings beat estimates, lifting shares 6.9%, as stronger Linzess sales expectations and profitability drive a higher 2026 outlook.
NASDAQ · IRWD
Healthcare · Drug Manufacturers - Specialty & Generic
$4.70
Down-$0.01 (-0.21%)
Updated Nov 21, 2026, 2:38 AM
SID Score
6.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IRWD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 20, 2026
IRWD closed at $4.70 after 21 trading sessions, up 35.84% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 20, 2026 | $4.655 | $4.865 | $4.645 | $4.70 | 3.02M |
| Nov 19, 2026 | $4.76 | $4.79 | $4.555 | $4.71 | 3.29M |
| Nov 18, 2026 | $4.85 | $4.94 | $4.7011 | $4.78 | 2.22M |
| Nov 17, 2026 | $4.83 | $4.89 | $4.765 | $4.87 | 2.82M |
| Nov 16, 2026 | $4.81 | $4.915 | $4.7609 | $4.85 | 3.11M |
| Nov 13, 2026 | $4.84 | $4.90 | $4.7601 | $4.83 | 2.81M |
| Nov 12, 2026 | $4.83 | $4.995 | $4.79 | $4.85 | 3.57M |
| Nov 11, 2026 | $4.81 | $4.93 | $4.74 | $4.87 | 2.82M |
| Nov 10, 2026 | $4.68 | $4.968 | $4.65 | $4.81 | 4.59M |
| Nov 9, 2026 | $4.50 | $4.76 | $4.345 | $4.68 | 5.33M |
| Nov 6, 2026 | $4.26 | $4.44 | $4.10 | $4.39 | 3.96M |
| Nov 5, 2026 | $4.30 | $4.41 | $3.84 | $4.03 | 4.99M |
| Nov 4, 2026 | $3.61 | $3.80 | $3.58 | $3.77 | 2.57M |
| Nov 3, 2026 | $3.51 | $3.57 | $3.40 | $3.50 | 1.95M |
| Nov 2, 2026 | $3.50 | $3.585 | $3.4332 | $3.46 | 1.3M |
| Oct 30, 2026 | $3.59 | $3.64 | $3.45 | $3.50 | 1.47M |
| Oct 29, 2026 | $3.65 | $3.695 | $3.575 | $3.62 | 1.37M |
| Oct 28, 2026 | $3.46 | $3.63 | $3.46 | $3.61 | 1.41M |
| Oct 27, 2026 | $3.52 | $3.545 | $3.45 | $3.51 | 1.66M |
| Oct 26, 2026 | $3.49 | $3.535 | $3.45 | $3.50 | 1.13M |
| Oct 23, 2026 | $3.52 | $3.536 | $3.38 | $3.46 | 1.26M |
The latest Smart Investors Daily articles mentioning IRWD.
Company
Market Activity
Research & News
IRWD research
Company profile and research snapshot.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 26, 2026 | Citizens | Market Outperform | — |
| Jan 5, 2026 | Wells Fargo | Equal-Weight | — |
| Jan 5, 2026 | Citizens | Market Outperform | — |
| Nov 11, 2025 | Wells Fargo | Equal-Weight | — |
| Apr 15, 2025 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Nov 6, 2026
Ironwood's Q3 earnings beat estimates, lifting shares 6.9%, as stronger Linzess sales expectations and profitability drive a higher 2026 outlook.
SeekingAlpha · Nov 6, 2026
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2026 Earnings Call November 5, 2026 8:30 AM ESTCompany ParticipantsChris Stamm - Vice President of Investor...
SeekingAlpha · Nov 6, 2026
2026-11-06. The following slide deck was published by Ironwood Pharmaceuticals, Inc.
Yahoo · Nov 6, 2026
Ironwood Pharmaceuticals Inc (IRWD) lifted full-year 2026 LINZESS net sales guidance to $1.2-$1.25 billion after record quarterly sales of $325 million and $98 million in adjusted EBITDA.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning IRWD.